Lymphoma, T Cell, Cutaneous Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • Registry of patients (exposure is Cutaneous Lymphoma)
  • Barcelona, Spain
  • +13 more
2022-03-15
Mar 15, 2022
T
Recruiting
  • Hodgkin Disease
  • Lymphoma, T-Cell, Cutaneous
  • No Intervention
  • San Bartolome, Alicante, Spain
  • +29 more
2022-03-10
Mar 10, 2022
4
Recruiting
  • Mycosis Fungoides
  • +2 more
  • Graz, Austria
  • +67 more
2022-01-27
Jan 27, 2022
E
Recruiting
  • Mycosis Fungoides
  • +2 more
  • Naloxone Hydrochloride Lotion, 0.5%
  • Placebo Lotion
  • Birmingham, Alabama
  • +31 more
2022-01-18
Jan 18, 2022
P
Terminated
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Bydgoszcz, Poland
    Centrum Onkologii im. prof. F. Łukaszczyka
2021-12-23
Dec 23, 2021
E
Recruiting
  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous
  • Nagoya, Japan
  • +2 more
2021-11-16
Nov 16, 2021
I
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • single-arm, non-randomized Biodynamic imaging (BDI)
  • Indianapolis, Indiana
    Indiana University School of Medicine, Department of Dermatology
2021-11-17
Nov 17, 2021
E
Withdrawn
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides/Sezary Syndrome
  • Zürich, Switzerland
    UniversitaetsSpital Zurich - Division of Dermatology
2021-08-31
Aug 31, 2021
S
Active, not recruiting
  • Mycoses
  • +5 more
  • anti-thymocyte globulin
  • +2 more
  • Stanford, California
    Stanford University School of Medicine
2021-07-29
Jul 29, 2021
I
Recruiting
  • Lymphoma, T-Cell
  • +2 more
  • IPH4102
  • Birmingham, Alabama
  • +42 more
2021-05-28
May 28, 2021
C
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +2 more
    • New York, New York
      Columbia University Medical Center
    2021-03-10
    Mar 10, 2021
    U
    Terminated
    • Lymphoma, T-Cell, Cutaneous
    • +6 more
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    2021-01-20
    Jan 20, 2021
    P
    Recruiting
    • Lymphoma, T-Cell, Cutaneous
    • +2 more
    • Lenalidomide 15mg
    • Brentuximab Vedotin 1.8 mg/Kg
    • Melbourne, Victoria, Australia
      Peter MacCallum Cancer Centre
    2020-09-29
    Sep 29, 2020
    S
    No longer available
    • Disease, Hodgkin
    • +3 more
    • brentuximab vedotin
    • Stanford, California
    • +30 more
    2020-09-17
    Sep 17, 2020
    E
    Active, not recruiting
    • Lymphoma, T-Cell, Cutaneous
    • Mycosis Fungoides/Sezary Syndrome
    • Madrid, Spain
    • +1 more
    2020-07-30
    Jul 30, 2020
    A
    Completed
    • Lymphoma, T-Cell, Cutaneous
    • New York, New York
      Center for Lymphoid Malignancies
    2020-07-14
    Jul 14, 2020
    R
    Completed
    • Lymphoma, T-Cell, Peripheral
    • Lymphoma, T-Cell, Cutaneous
    • Duarte, California
    • +7 more
    2019-12-23
    Dec 23, 2019
    Y
    Withdrawn
    • Lymphoma, T-Cell, Cutaneous
    • Intratumoral G100
    • (no location specified)
    2019-12-16
    Dec 16, 2019
    M
    No longer available
    • Lymphoma, T-Cell, Cutaneous
    • Comparator: vorinostat
    • (no location specified)
    2019-08-13
    Aug 13, 2019
    J
    Unknown status
    • Lymphoma, T-Cell, Cutaneous
    • Bronx, New York
      James J Peters Bronx Veterans Affairs Medical Center
    2019-08-12
    Aug 12, 2019
    C
    Completed
    • Lymphoma, T-Cell, Cutaneous
    • Sézary Syndrome
      • New York, New York
        Columbia University Medical Center
      2017-02-06
      Feb 6, 2017
      J
      Completed
      • Lymphoma, T-Cell, Cutaneous
      • Quisinostat, 12 mg
      • Pittsburgh, Pennsylvania
      • +12 more
      2016-11-02
      Nov 2, 2016
      T
      Completed
      • Lymphoma, T-Cell, Cutaneous
      • placebo for SHAPE (SHP-141)
      • +3 more
      • Stanford, California
      • +5 more
      2016-02-23
      Feb 23, 2016
      S
      Completed
      • Hodgkin Disease
      • +4 more
      • SGN-30 (monoclonal antibody)
      • Birmingham, Alabama
      • +9 more
      2011-10-07
      Oct 7, 2011